Related Experiment Video

Updated: Jun 7, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

An MLH1 mutation links BACH1/FANCJ to colon cancer, signaling, and insight toward directed therapy

Jenny Xie1, Shawna Guillemette, Min Peng

  • 11Department of Cancer Biology, University of Massachusetts Medical School, Women's Cancers Program, UMass Memorial Cancer Center, Worcester, Massachusetts 01605, USA.

Cancer Prevention Research (Philadelphia, Pa.)
|October 28, 2010
PubMed

Insights

A specific MLH1 mutation disrupts its interaction with FANCJ, delaying DNA repair signaling. This delay impacts hereditary nonpolyposis colon cancer (HNPCC) development and suggests new therapeutic strategies.

Area of Science:

  • Molecular biology
  • Genetics
  • Cancer research

Background:

  • Defects in MLH1 and other mismatch repair (MMR) proteins are primary causes of hereditary nonpolyposis colon cancer (HNPCC).
  • Some HNPCC-associated mutations have unknown pathogenicity, necessitating further investigation into their mechanisms.

Purpose of the Study:

  • To investigate the functional consequences of an MLH1 clinical mutation (L607H) on MLH1 binding to FANCJ.
  • To elucidate the role of the MLH1-FANCJ interaction in DNA mismatch repair (MMR) signaling and cellular responses to DNA damage.

Main Methods:

  • Characterization of an MLH1 clinical mutation (L607H) affecting MLH1 binding to the DNA helicase FANCJ.
  • Analysis of MMR signaling and apoptotic responses in FANCJ-deficient cells.
  • Assessment of cellular resistance and sensitivity to DNA damaging agents.

Main Results:

  • The MLH1(L607H) mutation ablates MLH1 binding to FANCJ.
  • FANCJ deficiency leads to delayed MMR signaling and apoptotic responses, conferring resistance to O(6)-methylguanine lesions by allowing MGMT-mediated DNA repair.
  • This altered balance between MGMT-prosurvival and MMR-prodeath pathways explains microsatellite-stable HNPCC cases with intact MMR.
  • Loss of the FANCJ/MLH1 interaction sensitizes cells to DNA cross-linking agents.

Conclusions:

  • The MLH1-FANCJ interaction is crucial for timely MMR signaling and apoptosis, influencing cancer development.
  • The findings provide a molecular explanation for certain types of HNPCC and identify FANCJ as a potential therapeutic target.

More Related Videos

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

Related Concept Videos

Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair01:36

Mismatch Repair

Overview
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...